The relation of visceral adiposity index and lipid accumulation product with metabolic, anthropometric, and hormonal parameters in patients with polycystic ovary syndrome

Aim: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age and is associated with glucose intolerance, central obesity, hypertension, and dyslipidemia. The Visceral Adiposity Index (VAI) and Lipid Accumulation Product (LAP) are effective indices for predicting insulin resistance are associated with cardiovascular and cerebrovascular events. In this study, we aimed to investigate the relationship of VAI and LAP with metabolic, anthropometric, and hormonal parameters in PCOS patients. Methods: A total of 106 patients with PCOS who were diagnosed according to the Rotterdam criteria and 66 healthy controls without PCOS aged 18-35 years were included in this prospective, case-control study. Patients with diabetes mellitus, Cushing syndrome, hyperprolactinemia, congenital adrenal hyperplasia, hypertension, or thyroid disorder were excluded. The VAI and LAP were calculated based on the high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels. Results: There was a negative, significant correlation between LAP and HDL-C (r=-0.644), a positive, significant correlation between TG (r=0.706) and hip circumference (r=0.872), and a positive, significant correlation between VAI and waist circumference (r=0.625) in the PCOS group. There was also a positive, significant correlation between HOMA-IR and VAI in the PCOS group (r=0.462). Conclusion: Our study results suggest that VAI seems to be a more useful index for predicting insulin resistance in PCOS patients.